In a landmark study published in Science Advances (Antibiotics damage the colonic mucus barrier in a microbiota-independent manner), Dr. Shai Bel and his research team at the Azrieli Faculty of Medicine of Bar-Ilan University have uncovered crucial insights into how antibiotic use increases the risk of inflammatory bowel disease (IBD).
The study demonstrates that antibiotics interfere with the protective mucus layer in the intestine, a discovery that could reshape our understanding of antibiotic effects and IBD development.
IBD, which includes Crohn’s disease and ulcerative colitis, affects approximately 1% of the global population. This debilitating condition is marked by the erosion of the mucosal layer that serves as a critical barrier between the gut microbiome and the immune system. Despite ongoing research, the exact causes of IBD remain unclear. However, previous studies have indicated a link between antibiotic use and an increased risk of developing IBD.
Dr. Bel’s latest research sheds new light on this association. “We have discovered that antibiotic use damages the protective mucus layer that separates the immune system in the gut from the microbiome,” says Dr. Bel. His team’s study reveals that antibiotics, whether administered orally or via injection, disrupt this vital mucus layer, facilitating bacterial penetration and increasing the risk of gut inflammation.
Utilizing advanced techniques such as RNA sequencing, machine learning, and mucus secretion measurement, the researchers examined the effects of antibiotics using mice models. The study found that antibiotics hinder the secretion of protective mucus, leading to bacterial infiltration, systemic bacterial antigen replication, and ulcer development — hallmarks of IBD.
One of the most striking findings of the study is that antibiotics’ impact on the mucus barrier is not due to alterations in the microbiome but rather affects the cells in the intestinal wall responsible for mucus production. “This finding shatters the paradigm that antibiotics harm only bacteria and not our cells,” Dr. Bel explains.
As a next step, the research team plans to explore potential treatments that could mitigate the adverse effects of antibiotics on mucus secretion. These findings not only advance our understanding of IBD but also underscore the need for careful consideration of antibiotic use and its broader implications for gut health.
